NewAmsterdam Pharma Short Term Debt Over Time
| NAMS Stock | 23.80 0.30 1.28% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out NewAmsterdam Pharma Performance and NewAmsterdam Pharma Correlation. NewAmsterdam |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NewAmsterdam Pharma. If investors know NewAmsterdam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NewAmsterdam Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.56) | Revenue Per Share | Quarterly Revenue Growth 14.905 | Return On Assets | Return On Equity |
The market value of NewAmsterdam Pharma is measured differently than its book value, which is the value of NewAmsterdam that is recorded on the company's balance sheet. Investors also form their own opinion of NewAmsterdam Pharma's value that differs from its market value or its book value, called intrinsic value, which is NewAmsterdam Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NewAmsterdam Pharma's market value can be influenced by many factors that don't directly affect NewAmsterdam Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NewAmsterdam Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if NewAmsterdam Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NewAmsterdam Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Short Term Debt Analysis
Compare NewAmsterdam Pharma and related stocks such as Monte Rosa Therapeutics, Inventiva Sa, and Cullinan Oncology LLC Short Term Debt Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLUE | 750 K | 750 K | 750 K | 750 K | 750 K | 750 K | 750 K | 750 K | 750 K | 750 K | 6.3 M | 6.3 M | 6.3 M | 3.2 M | 3.6 M | 3.7 M |
| IVA | 60.9 K | 60.9 K | 60.9 K | 60.9 K | 58.7 K | 194 K | 145.7 K | 262.1 K | 2.1 M | 2.1 M | 18 K | 1.3 M | 5.9 M | 5.3 M | 6.1 M | 6.4 M |
| CGEM | 972.8 K | 972.8 K | 972.8 K | 972.8 K | 1.1 M | 1.1 M | 330.4 K | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.4 M | 1.3 M | 1.2 M |
| CMPX | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 5.6 M | 7.5 M | 989 K | 1.1 M | 1.2 M | 1.1 M | 1 M |
| REPL | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 6.9 M | 7.3 M | 3.8 M | 7.8 M | 8.9 M | 6.4 M |
| CRNX | 49 K | 49 K | 49 K | 49 K | 49 K | 49 K | 49 K | 724 K | 724 K | 724 K | 835 K | 939 K | 1.1 M | 4.2 M | 7.2 M | 7.5 M |
| PRTC | 1.5 M | 1.5 M | 1.5 M | 4.3 M | 6.9 M | 5 M | 7 M | 7.5 M | 12 M | 4.4 M | 29.7 M | 9.4 M | 12.5 M | 7.1 M | 8.2 M | 9.8 M |
| MRUS | 225.2 K | 225.2 K | 225.2 K | 230.6 K | 203.1 K | 182.6 K | 175.6 K | 9.8 M | 292.8 K | 1.4 M | 1.4 M | 1.5 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M |
| MLYS | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4 M | 3.6 M |
| ANEB | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 181.2 K | 161 K |
| JANX | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 751 K | 388 K | 1.5 M | 1.5 M | 1.7 M | 1.3 M |
| RZLT | 3.7 M | 3.7 M | 3.7 M | 60 K | 153.9 K | 83.1 K | 10 K | 3.4 M | 10 K | 245 K | 530 K | 108 K | 541 K | 568 K | 511.2 K | 631.7 K |
| MOLN | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.1 M | 1.4 M |
| PEPG | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 3 M | 3.1 M | 4.6 M |
NewAmsterdam Pharma and related stocks such as Monte Rosa Therapeutics, Inventiva Sa, and Cullinan Oncology LLC Short Term Debt description
My Equities
My Current Equities and Potential Positions
| NewAmsterdam Pharma | NAMS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Netherlands |
| Exchange | NASDAQ Exchange |
null 22.64
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.